Summit Trail Advisors’s Novartis NVS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$3.18M Buy
20,845
+16,957
+436% +$2.6M 0.05% 289
2025
Q4
$536K Sell
3,888
-3,169
-45% -$415K 0.01% 1052
2025
Q3
$905K Buy
7,057
+500
+8% +$61K 0.01% 889
2025
Q2
$793K Buy
6,557
+197
+3% +$22.2K 0.01% 557
2025
Q1
$734K Buy
6,360
+580
+10% +$61.7K 0.02% 194
2024
Q4
$562K Buy
5,780
+603
+12% +$64.3K 0.02% 197
2024
Q3
$595K Sell
5,177
-376
-7% -$42.7K 0.01% 361
2024
Q2
$591K Buy
5,553
+956
+21% +$96K 0.02% 337
2024
Q1
$462K Buy
4,597
+274
+6% +$28.1K 0.01% 351
2023
Q4
$436K Buy
4,323
+685
+19% +$66.1K 0.01% 308
2023
Q3
$371K Sell
3,638
-623
-15% -$63.2K 0.01% 332
2023
Q2
$430K Buy
4,261
+716
+20% +$71.6K 0.02% 295
2023
Q1
$326K Buy
+3,545
New +$310K 0.01% 305
2022
Q1
Sell
-3,445
Closed -$301K 363
2021
Q4
$301K Buy
+3,445
New +$286K 0.02% 232
2018
Q4
Sell
-4,741
Closed -$366K 192
2018
Q3
$366K Buy
4,741
+768
+19% +$56.8K 0.08% 130
2018
Q2
$269K Sell
3,973
-21,717
-85% -$1.5M 0.09% 114
2018
Q1
$1.48M Buy
25,690
+4,992
+24% +$380K 0.25% 87
2017
Q4
$1.68M Buy
+20,698
New +$1.56M 0.21% 90

Other funds holding NVS

Summit Trail Advisors's NVS Position: Q1 2026 in Review

Summit Trail Advisors increased its Novartis (NVS) stake by 436% in Q1 2026, buying an estimated $2.6M and bringing the position to 20,845 shares worth $3.18M. The position accounts for 0.05% of the portfolio, ranked #289.

Summit Trail Advisors first reported a position in NVS in Q4 2017 and has held it in 18 quarters since. 1,591 funds tracked by Wall St. Rank hold NVS as of Q1 2026.

  • Summit Trail Advisors held 20,845 shares of Novartis worth $3.18M as of Q1 2026.
  • Summit Trail Advisors bought 16,957 Novartis shares in Q1 2026, an estimated $2.6M.
  • Novartis made up 0.05% of Summit Trail Advisors's portfolio in Q1 2026, its #289 holding.
  • Summit Trail Advisors first reported a position in Novartis in Q4 2017 and has held it in 18 quarters since.
  • 1,591 funds tracked by Wall St. Rank held Novartis as of Q1 2026.

Based on Summit Trail Advisors's 13F filing for Q1 2026, filed 12 May 2026.